Isimig (Frovatriptan Succinate Monohydrate)

Frovatriptan is a selective serotonin 5‑HT1B/1D receptor agonist. By stimulating these receptors on cranial blood vessels and trigeminal nerve endings, it causes vasoconstriction and blocks the release of neuropeptides that trigger migraine pain, thereby aborting the attack.

The prescribing physician determines the appropriate dose for each patient based on clinical guidelines and individual response. Typically, a single oral tablet is taken at the onset of a migraine, and the prescriber may advise on repeat dosing if needed.

Safety data for frovatriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Isimig product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with shorter‑acting triptans such as sumatriptan, frovatriptan has a longer half‑life, which can provide more sustained migraine relief and may reduce the need for repeat dosing. However, onset of relief may be slightly slower, and individual response varies.

Store Isimig tablets at room temperature, below 25 °C, in the original blister pack. Keep the medication away from moisture, heat, and direct sunlight to maintain stability and potency.

Isimig is taken orally as a whole tablet with a glass of water. It should be swallowed whole and not chewed or crushed. The tablet is usually taken at the first sign of a migraine attack.

Serious risks include coronary artery spasm or myocardial infarction, especially in patients with underlying cardiovascular disease, and serotonin syndrome when combined with other serotonergic agents. Immediate medical attention is required if chest pain, severe hypertension, or signs of an allergic reaction occur.

Isimig is contraindicated in patients with a history of coronary artery disease, uncontrolled hypertension, peripheral vascular disease, or known hypersensitivity to frovatriptan or any component of the tablet. It should also be avoided in individuals who have taken ergot derivatives within 24 hours.